Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) have been given an average recommendation of “Moderate Buy” by the seventeen brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $30.35.

Several analysts have recently weighed in on NRIX shares. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 target price for the company. UBS Group assumed coverage on shares of Nurix Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $35.00 price target for the company. BTIG Research started coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective for the company. Stephens restated an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Monday, October 14th. Finally, HC Wainwright boosted their price objective on Nurix Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, December 11th.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,546 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. This represents a 9.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total transaction of $83,519.10. Following the completion of the transaction, the insider now directly owns 50,670 shares in the company, valued at approximately $1,231,281. This trade represents a 6.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 9,351 shares of company stock valued at $227,158. Company insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On Nurix Therapeutics

A number of large investors have recently made changes to their positions in NRIX. Bank of New York Mellon Corp raised its holdings in shares of Nurix Therapeutics by 31.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 209,136 shares of the company’s stock valued at $4,365,000 after purchasing an additional 49,918 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Nurix Therapeutics by 14.2% in the second quarter. Rhumbline Advisers now owns 88,781 shares of the company’s stock worth $1,853,000 after buying an additional 11,010 shares during the last quarter. TD Asset Management Inc bought a new stake in shares of Nurix Therapeutics during the 2nd quarter worth about $593,000. Arizona State Retirement System acquired a new position in shares of Nurix Therapeutics during the 2nd quarter valued at about $295,000. Finally, Renaissance Technologies LLC raised its stake in shares of Nurix Therapeutics by 80.7% in the 2nd quarter. Renaissance Technologies LLC now owns 324,000 shares of the company’s stock valued at $6,762,000 after acquiring an additional 144,700 shares in the last quarter.

Nurix Therapeutics Stock Down 1.8 %

Shares of NASDAQ:NRIX opened at $19.14 on Friday. The company has a 50 day moving average of $21.14 and a two-hundred day moving average of $22.45. Nurix Therapeutics has a 52-week low of $7.65 and a 52-week high of $29.56. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -6.58 and a beta of 2.14.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.